3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
2
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
156
Neoplasms
115
Colorectal Neoplasms
98
Breast Neoplasms
93
Pancreatic Neoplasms
81
Neoplasm Metastasis
81
Leukemia, Myeloid, Acute
79
Recurrence
76
Prostatic Neoplasms
74
Ovarian Neoplasms
74
Melanoma
74
Multiple Myeloma
66
Stomach Neoplasms
59
Lung Neoplasms
56
Squamous Cell Carcinoma of Head and Neck
55
Triple Negative Breast Neoplasms
50
Glioblastoma
49
Lymphoma
47
Endometrial Neoplasms
43
Carcinoma, Hepatocellular
42
Advanced Solid Tumor
42
Lymphoma, Non-Hodgkin
41
Precursor Cell Lymphoblastic Leukemia-Lymphoma
40
Advanced Solid Tumors
37
Small Cell Lung Carcinoma
35
Uterine Cervical Neoplasms
34
Carcinoma, Renal Cell
34
Lymphoma, Large B-Cell, Diffuse
32
Lymphoma, B-Cell
32
Sarcoma
30
Interventions
pembrolizumab
1
olaparib
1
lenvatinib
1
enzalutamide
1
belzutifan
1
Prednisone
1
Etoposide
1
Docetaxel
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recruiting
×
Metastatic Castration-Resistant Prostate Cancer
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled